Complexation of 188Re-phosphonates: In vitro and in vivo studies

Radiochimica Acta

Volumn 91, Issue 10, 2003, Pages 607-612

  Faintuch, B L ^a   Faintuch, S ^b   Muramoto, E ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

188Re EDTMP; 188Re HEDP; 188Re MDP; Radiopharmaceuticals

Indexed keywords

ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); ETIDRONIC ACID; MEDRONIC ACID; RADIOPHARMACEUTICAL AGENT; RHENIUM 188;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BONE CANCER; CANCER PAIN; COMPLEX FORMATION; CONCENTRATION RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FEMUR FRACTURE; HEATING; KIDNEY TUBULE ABSORPTION; MOUSE; MUSCLE; NONHUMAN; RADIOCHEMISTRY; REACTION ANALYSIS; REACTION TIME;

EID: 0141927435     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.91.10.607.22474     Document Type: Article

References (29)

1. Pons, F., Fuster, D.: Under utilization of radionuclide therapy in metastatic bone pain palliation (Editorial). Nucl. Med. Commun. 23, 301 (2002).
2. Garret, I. R.: Bone destruction in cancer. Semin. Oncol. 20, 4 (1993).
3. Hoskin, P. J.: Palliation of bone metastases. Eur. J. Cancer 27,950 (1991).
4. Price, P., Hoskin, P. J., Easton, P., Austin, D., Palmer, S. G., Yarnold, J. R.: Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bone metastases. Clin. Oncol. 1, 59 (1989).
5. Tannock, I.: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J. Nucl. Oncol. 3, 1013 (1985).
6. Pecher, C.: Biological investigation with radioactive calcium and strontium. Proc. Soc. Exp. Biol. Med. 46, 86 (1941).
7. McCreary, V. R., O'Sullivan, J. M.: Future directions for unsealed source radionuclide therapy for bone metastases (Editorial). Eur. J. Nucl. Med., DOI 10.1007/s 00259-002-0914-2. Published online: 16 August (2002).
8. Lewington, V. J.: A prospective randomized double-blind cross-over study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer 27, 954 (1991).
9. Friedell, H. L., Storaasli, J. P.: The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to the bone. Am. J. Roentgenol. 64, 559 (1950).
10. Resche, I., Chatal, J. F., Peching, A.: A dose-controlled study of Sm-53-EDTMP in the treatment of patients with painful bone metastases. Eur. J. Cancer 33, 1583 (1997).
11. Neves, M., Gano, L., Pereira, N., Costa, M. C., Costa, M. R., Chandia, M., Rosado, M., Fausto, R.: Synthesis, characterization and biodistribution of biphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl. Med. Biol. 29, 329 (2002).
12. 186Re-1, 1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J. Nucl. Med 41, 647 (2000).
13. 188Re, and a study of its stability. Appl. Radiat. Isot. 49, 351 (1998).
14. Knapp, Jr., F. F., Mirzadeh, S., BEETS, A. L., O'Doherty, M., Blower, P. J., Verdera, E. S., Gaudiano, J. S., Kropp, J., Guhlke, J., Palmedo, H., Biersack, H. J.: Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl. Radiat. Isot. 49, 309 (1998).
15. 188Re]Rhenium sulfide suspension: A potential radiopharmaceutical for tumor treatment following intratumor injection. Nucl. Med. Biol. 26, 573 (1999).
16. Jurisson, S., Berning, D., Jia, W., Ma, D.: Coordination compounds in nuclear medicine. Chem. Ver. 93, 1137 (1993).
17. Davis, M. A., Jones, A. G.: Comparison of Tc-99m labelled phosphate and phosphonate agents for skeletal imaging. Sem. Nucl. Med. 6, 19 (1976).
18. Collins, D., Eary, J. F. C., Donaldson, G., Vernon, D., Bush, N. E., Petersdorf, S., Livingston, R. B., Gordon, E. E., Chapman, C. R., Applebaum, F. R.: Samarium-153EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase 1 trial. J. Nucl. Med. 34, 1839 (1993).
19. Turner, J. H., Claringbold, P. G.: A phase 2 study of treatment of painful multofocal skletal metastases with single and repeated dose Sm-153 EDTMP. Eur. J. Cancer 27, 1084 (1991).
20. Farhangui, H., Holmes, R. A.: Sm-153 EDTMP pharmacokinetics, toxicity and pain response using escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med. 33, 1451 (1992).
21. Campa, J. A., Payne, R.: The management of intractable bone pain: a clinician's perspective. Semin. Nucl. Med. 22, 3 (1992).
22. Nielsen, O. S., Munro, A. J., Tannock, I. F.: Bone metastases: pathophysiology and management policy. J. Clin. Oncol. 9, 509 (1991).
23. nd edn., Interscience Publishers, New York (1966).
24. John, E., Thakur, M. L., Defulvio, J., McDevitt, M. R., Damjanov, I.: Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J. Nucl. Med. 34, 260 (1993).
25. 188Reethylenediamine-N,N,N′,N′-tetrakis (methylene phosphonic acid) as a potential agent for bone pain palliation. Nucl. Med. Commun. 23, 75 (2002).
26. Hsieh, B. T., Hsieh, J. F., Tsai, S. C., Lin, W. Y., Wang, S. J., Ting, G.: Comparison of various thenium-188-labeled diphosphonates for the treatment of bone metastases. Nucl. Med. Biol. 26, 973 (1999).
27. 188Re-EDTMP as a potential therapeutic bone agent. J. Nucl. Med. 42, 261P (2001).
28. Verdera, E. S., Gaudiano, J., León, A., Martinez, G., Robles, A., Savio, E., León, E., McPherson, D. W., Knapp Jr., F. F.: Rhenium-188-HEDP-kit formulation and quality control. Radiochim. Acta 79, 113 (1997).
29. Goeckler, W. F., Edwards, B., Volkert, W. A., Holmes, R. A., Simon, J., Wilson, D.: Skeletal localisation of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 28, 495 (1987).